{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:20:00Z","timestamp":1792981200468,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41571-026-01126-1","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:39:17Z","timestamp":1771598357000},"page":"356-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4093-2681","authenticated-orcid":false,"given":"Giulia","family":"Martini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Boscolo","family":"Bielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4661-5540","authenticated-orcid":false,"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"1126_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013262 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1126_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"1126_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20407","volume":"3","author":"WH Abualkhair","year":"2020","unstructured":"Abualkhair, W. H. at al. Trends in incidence of early-onset colorectal cancer in the United States among those approaching screening age. JAMA Netw. Open 3, e1920407 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1126_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41416-025-03303-y","volume":"134","author":"RS Laskar","year":"2026","unstructured":"Laskar, R. S. et al. A prospective investigation of early-onset colorectal cancer risk factors \u2014 pooled analysis of three large-scale European cohorts. Br. J. Cancer\u00a0134, 781\u2013789 (2026).","journal-title":"Br. J. Cancer"},{"key":"1126_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1001\/jama.2025.10218","volume":"334","author":"T Jayakrishnan","year":"2025","unstructured":"Jayakrishnan, T. & Ng, K. Early-onset gastrointestinal cancers: a review. JAMA. 334, 1373\u20131385 (2025).","journal-title":"JAMA."},{"key":"1126_CR6","first-page":"372","volume":"72","author":"F Ciardiello","year":"2022","unstructured":"Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J. Clin. 72, 372\u2013401 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"1126_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes, A. et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 10\u201332 (2023).","journal-title":"Ann. Oncol."},{"key":"1126_CR8","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757\u20131765 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1126_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2468-1253(23)00479-X","volume":"9","author":"S Napolitano","year":"2024","unstructured":"Napolitano, S. et al. Targeting the EGFR signaling pathway in metastatic colorectal cancer. Lancet Gastroenterol. Hepatol. 9, 664\u2013676 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1126_CR10","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","volume":"392","author":"E Elez","year":"2025","unstructured":"Elez, E. et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer. N. Engl. J. Med. 392, 2425\u20132437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1126_CR11","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Pembrolizumab in microsatellite instability high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1126_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","volume":"32","author":"LA Diaz Jr","year":"2014","unstructured":"Diaz, L. A. Jr & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579\u2013586 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1126_CR13","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1126_CR14","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","volume":"4","author":"S Misale","year":"2014","unstructured":"Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S. & Bardelli, A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4, 1269\u20131280 (2014).","journal-title":"Cancer Discov."},{"key":"1126_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.830816","volume":"24","author":"Yang","year":"2022","unstructured":"Yang et al. Longitudinal circulating tumor DNA profiling in metastatic colorectal cancer during anti-EGFR therapy. Front. Oncol. 24, 830816 (2022).","journal-title":"Front. Oncol."},{"key":"1126_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221096878","volume":"14","author":"V Caputo","year":"2022","unstructured":"Caputo, V. et al. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Ther. Adv. Med. Oncol. 14, 17588359221096878 (2022).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1126_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.07.007","volume":"70","author":"N Normanno","year":"2018","unstructured":"Normanno, N., Cervantes, A., Ciardiello, F., De Luca, A. & Pinto, C. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios. Cancer Treat. Rev. 70, 1\u20138 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"1126_CR18","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1074\/jbc.C113.532267","volume":"289","author":"C Kahlert","year":"2014","unstructured":"Kahlert, C. et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J. Biol. Chem. 289, 3869\u20133875 (2014).","journal-title":"J. Biol. Chem."},{"key":"1126_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11523-021-00795-5","volume":"16","author":"G Patelli","year":"2021","unstructured":"Patelli, G. et al. Liquid biopsy for prognosis and treatment in metastatic colorectal cancer: circulating tumor cells vs circulating tumor DNA. Target. Oncol. 16, 309\u2013324 (2021).","journal-title":"Target. Oncol."},{"key":"1126_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz042","volume":"3","author":"S Bach","year":"2019","unstructured":"Bach, S. et al. Circulating tumor DNA analysis: clinical implications for colorectal cancer patients. a systematic review. JNCI Cancer Spectr. 3, pkz042 (2019).","journal-title":"JNCI Cancer Spectr."},{"key":"1126_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124\u20131131 (2019).","journal-title":"JAMA Oncol."},{"key":"1126_CR22","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-23-0079","volume":"29","author":"G Patelli","year":"2023","unstructured":"Patelli, G. et al. Circulating tumor DNA to drive treatment in metastatic colorectal cancer. Clin. Cancer Res. 29, 4530\u20134539 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR23","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1126_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101196","volume":"4","author":"SM Batool","year":"2023","unstructured":"Batool, S. M. et al. Extrinsic and intrinsic preanalytical variables affecting liquid biopsy in cancer. Cell Rep. Med. 4, 101196 (2023).","journal-title":"Cell Rep. Med."},{"key":"1126_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.nbt.2019.09.006","volume":"55","author":"F Salvianti","year":"2020","unstructured":"Salvianti, F. et al. The pre-analytical phase of the liquid biopsy. N. Biotechnol. 55, 19\u201329 (2020).","journal-title":"N. Biotechnol."},{"key":"1126_CR26","first-page":"259","volume":"6","author":"FJ Illana","year":"2025","unstructured":"Illana, F. J. et al. Circulating tumor DNA in patients with cancer: insights from clinical laboratory. Adv. Lab. Med. 6, 259\u2013276 (2025).","journal-title":"Adv. Lab. Med."},{"key":"1126_CR27","doi-asserted-by":"publisher","first-page":"16368","DOI":"10.1073\/pnas.0507904102","volume":"102","author":"F Diehl","year":"2005","unstructured":"Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl Acad. Sci. USA 102, 16368\u201316373 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1126_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.annonc.2024.12.006","volume":"36","author":"B Mart\u00ednez-Castedo","year":"2025","unstructured":"Mart\u00ednez-Castedo, B. et al. Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Ann. Oncol. 36, 263\u2013276 (2025).","journal-title":"Ann. Oncol."},{"key":"1126_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.766","volume":"5","author":"L Li","year":"2024","unstructured":"Li, L. & Sun, Y. Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges. MedComm 5, e766 (2024).","journal-title":"MedComm"},{"key":"1126_CR30","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s43018-025-00960-z","volume":"6","author":"J Mart\u00edn-Arana","year":"2025","unstructured":"Mart\u00edn-Arana, J. et al. Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Nat. Cancer 6, 1000\u20131016 (2025).","journal-title":"Nat. Cancer"},{"key":"1126_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27368-3","volume":"8","author":"L Dong","year":"2018","unstructured":"Dong, L., Wang, S., Fu, B. & Wang, J. Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection. Sci. Rep. 8, 9650 (2018).","journal-title":"Sci. Rep."},{"key":"1126_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1634\/theoncologist.2019-0441","volume":"25","author":"R Gupta","year":"2020","unstructured":"Gupta, R. et al. Guardant360 circulating tumor DNA assay is concordant with FoundationOne next-generation sequencing in detecting actionable driver mutations in anti-EGFR naive metastatic colorectal cancer. Oncologist 25, 235\u2013243 (2020).","journal-title":"Oncologist"},{"key":"1126_CR33","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","volume":"30","author":"CD Rolfo","year":"2024","unstructured":"Rolfo, C. D. et al. Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation. Clin. Cancer Res. 30, 2452\u20132460 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102051","volume":"8","author":"Gimeno-Valiente","year":"2023","unstructured":"Gimeno-Valiente et al. Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer. ESMO Open 8, 102051 (2023).","journal-title":"ESMO Open"},{"key":"1126_CR35","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-17-3044","volume":"24","author":"CJ Gibson","year":"2018","unstructured":"Gibson, C. J. & Steensma, D. P. New insights from studies of clonal hematopoiesis. Clin. Cancer Res. 24, 4633\u20134642 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR36","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/1878-0261.12727","volume":"14","author":"HT Chan","year":"2020","unstructured":"Chan, H. T. et al. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Mol. Oncol. 14, 1719\u20131730 (2020).","journal-title":"Mol. Oncol."},{"key":"1126_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2767-9764.CRC-24-0522","volume":"5","author":"T Krishnan","year":"2025","unstructured":"Krishnan, T. et al. Clonal hematopoiesis of indeterminate potential and its association with treatment outcomes and adverse events in patients with solid tumors. Cancer Res. Commun. 5, 66\u201373 (2025).","journal-title":"Cancer Res. Commun."},{"key":"1126_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00228","volume":"7","author":"S Napolitano","year":"2023","unstructured":"Napolitano, S. et al. Novel clinical tool to estimate risk of false-negative KRAS mutations in circulating tumor DNA testing. JCO Precis Oncol. 7, e2300228 (2023).","journal-title":"JCO Precis Oncol."},{"key":"1126_CR39","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/annonc\/mdx112","volume":"28","author":"J Grasselli","year":"2017","unstructured":"Grasselli, J. et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann. Oncol. 28, 1294\u20131301 (2017).","journal-title":"Ann. Oncol."},{"key":"1126_CR40","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/annonc\/mdx125","volume":"28","author":"J Vidal","year":"2017","unstructured":"Vidal, J. et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann. Oncol. 28, 1325\u20131332 (2017).","journal-title":"Ann. Oncol."},{"key":"1126_CR41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/annonc\/mdx417","volume":"29","author":"N Normanno","year":"2018","unstructured":"Normanno, N. et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann. Oncol. 29, 112\u2013118 (2018).","journal-title":"Ann. Oncol."},{"key":"1126_CR42","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1200\/JCO.24.01174","volume":"43","author":"S Stintzing","year":"2025","unstructured":"Stintzing, S. et al. Baseline liquid biopsy in relation to tissue-based parameters in metastatic colorectal cancer: results from the randomized FIRE-4 (AIO-KRK-0114) study. J. Clin. Oncol. 43, 1463\u20131473 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1126_CR43","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/annonc\/mdw136","volume":"27","author":"F Ciardiello","year":"2016","unstructured":"Ciardiello, F. et al. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann. Oncol. 27, 1055\u20131061 (2016).","journal-title":"Ann. Oncol."},{"key":"1126_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101504","volume":"11","author":"PP Vitiello","year":"2019","unstructured":"Vitiello, P. P. et al. Clinical practice use of liquid biopsy to identify RAS\/BRAF mutations in patients with metastatic colorectal cancer (mCRC): a single institution experience. Cancers 11, 1504 (2019).","journal-title":"Cancers"},{"key":"1126_CR45","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/annonc\/mdy061","volume":"29","author":"JB Bachet","year":"2018","unstructured":"Bachet, J. B. et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann. Oncol. 29, 1211\u20131219 (2018).","journal-title":"Ann. Oncol."},{"key":"1126_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.05.022","volume":"189","author":"JB Bachet","year":"2023","unstructured":"Bachet, J. B. et al. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-na\u00efve metastatic colorectal cancer. An AGEO prospective study. Eur. J. Cancer 189, 112934 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1126_CR47","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2767-9764.CRC-25-0002","volume":"5","author":"R Yaeger","year":"2025","unstructured":"Yaeger, R. et al. Clinical validity of FoundationOne liquid CDx for detection of BRAFV600E in colorectal cancer. Cancer Res. Commun. 5, 1566\u20131573 (2025).","journal-title":"Cancer Res. Commun."},{"key":"1126_CR48","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","volume":"28","author":"C Cremolini","year":"2017","unstructured":"Cremolini, C. et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann. Oncol. 28, 3009\u20133014 (2017).","journal-title":"Ann. Oncol."},{"key":"1126_CR49","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.19.01254","volume":"37","author":"F Morano","year":"2019","unstructured":"Morano, F. et al. Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. J. Clin. Oncol. 37, 3099\u20133110 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1126_CR50","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","volume":"5","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio, F. et al. Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1268\u20131275 (2019).","journal-title":"JAMA Oncol."},{"key":"1126_CR51","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1158\/1078-0432.CCR-20-4699","volume":"27","author":"P Manca","year":"2021","unstructured":"Manca, P. et al. The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer. Clin. Cancer Res. 27, 2505\u20132514 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR52","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe, J. et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 329, 1271\u20131282 (2023).","journal-title":"JAMA."},{"key":"1126_CR53","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nat. Med. 30, 730\u2013739 (2024).","journal-title":"Nat. Med."},{"key":"1126_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1069370","volume":"13","author":"G Martini","year":"2023","unstructured":"Martini, G. et al. Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS\/BRAF wild type tumors at start of first line: the CAPRI 2 GOIM trial. Front. Oncol. 13, 1069370 (2023).","journal-title":"Front. Oncol."},{"key":"1126_CR55","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.annonc.2024.08.2334","volume":"35","author":"D Ciardiello","year":"2024","unstructured":"Ciardiello, D. et al. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS\/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial. Ann. Oncol. 35, 1105\u20131115 (2024).","journal-title":"Ann. Oncol."},{"key":"1126_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104511","volume":"10","author":"D Ciardiello","year":"2025","unstructured":"Ciardiello, D. et al. Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial. ESMO Open 10, 104511 (2025).","journal-title":"ESMO Open"},{"key":"1126_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115642","volume":"226","author":"D Ciardiello","year":"2025","unstructured":"Ciardiello, D. Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: findings from the CAPRI-2 GOIM study. Eur. J. Cancer 226, 115642 (2025).","journal-title":"Eur. J. Cancer"},{"key":"1126_CR58","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1158\/1078-0432.CCR-23-1041","volume":"29","author":"SJ Casak","year":"2023","unstructured":"Casak, S. J. et al. FDA approval summary: tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2-positive RAS wild-type colorectal cancer. Clin. Cancer Res. 29, 4326\u20134330 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR59","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1158\/1078-0432.CCR-24-2763","volume":"31","author":"F Meric-Bernstam","year":"2025","unstructured":"Meric-Bernstam, F. et al. ctDNA analysis in ERBB2-amplified colorectal cancer: biomarker analysis of the MyPathway trial. Clin. Cancer Res. 31, 2935\u20132944 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR60","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","volume":"36","author":"JM Riedl","year":"2025","unstructured":"Riedl, J. M. et al. Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors. Ann. Oncol. 36, 682\u2013692 (2025).","journal-title":"Ann. Oncol."},{"key":"1126_CR61","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1158\/1078-0432.CCR-22-3094","volume":"29","author":"L Tan","year":"2023","unstructured":"Tan, L. et al. A phase Ib\/II trial of combined BRAF and EGFR inhibition in BRAF V600E positive metastatic colorectal cancer and other cancers: the EVICT (erlotinib and vemurafenib in combination trial) study. Clin. Cancer Res. 29, 1017\u20131030 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR62","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","volume":"30","author":"S Kopetz","year":"2024","unstructured":"Kopetz, S. et al. Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nat. Med. 30, 3261\u20133271 (2024).","journal-title":"Nat. Med."},{"key":"1126_CR63","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531\u2013548 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1126_CR64","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"Siravegna","year":"2015","unstructured":"Siravegna et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795\u2013801 (2015).","journal-title":"Nat. Med."},{"key":"1126_CR65","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/annonc\/mdy509","volume":"30","author":"CM Parseghian","year":"2019","unstructured":"Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243\u2013249 (2019).","journal-title":"Ann. Oncol."},{"key":"1126_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102683","volume":"124","author":"D Ciardiello","year":"2024","unstructured":"Ciardiello, D. et al. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: a systematic review. Cancer Treat. Rev. 124, 102683 (2024).","journal-title":"Cancer Treat. Rev."},{"key":"1126_CR67","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi, A. et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat. Med. 28, 1612\u20131618 (2022).","journal-title":"Nat. Med."},{"key":"1126_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.annonc.2025.10.002","volume":"37","author":"P Cirac\u00ec","year":"2026","unstructured":"Cirac\u00ec, P. et al. Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO. Ann. Oncol. 37, 79\u201391 (2026).","journal-title":"Ann. Oncol."},{"key":"1126_CR69","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/jamaoncol.2023.0655","volume":"9","author":"Napolitano","year":"2023","unstructured":"Napolitano et al. Panitumumab plus trifluridine-tipiracil as anti-epidermal growth factor receptor rechallenge therapy for refractory RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Oncol. 9, 966\u2013970 (2023).","journal-title":"JAMA Oncol."},{"key":"1126_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105491","volume":"10","author":"D Ciardiello","year":"2025","unstructured":"Ciardiello, D. et al. Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial. ESMO Open 10, 105491 (2025).","journal-title":"ESMO Open"},{"key":"1126_CR71","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1200\/JCO.2025.43.16_suppl.3514","volume":"43","author":"Y Kagawa","year":"2025","unstructured":"Kagawa, Y. et al. Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS\/BRAF wild-type metastatic colorectal cancer (mCRC): the REMARRY & PURSUIT trials. J. Clin. Oncol. 43, 3514\u20133514 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1126_CR72","doi-asserted-by":"publisher","first-page":"S1576","DOI":"10.1016\/j.annonc.2025.09.044","volume":"36","author":"C Montagut","year":"2025","unstructured":"Montagut, C. et al. Circulating tumour (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): final results of the phase II randomized CITRIC trial [abstract LBA33]. Ann. Oncol. 36, S1576\u2013S1577 (2025).","journal-title":"Ann. Oncol."},{"key":"1126_CR73","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/1878-0261.12547","volume":"13","author":"E Elez","year":"2019","unstructured":"Elez, E. et al. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. Mol. Oncol. 13, 1827\u20131835 (2019).","journal-title":"Mol. Oncol."},{"key":"1126_CR74","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s, G. et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1291\u20131305 (2020).","journal-title":"Ann. Oncol."},{"key":"1126_CR75","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey, A. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N. Engl. J. Med. 378, 1177\u20131188 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1126_CR76","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","volume":"404","author":"C Eng","year":"2024","unstructured":"Eng, C. et al. Colorectal cancer. Lancet. 404, 294\u2013310 (2024).","journal-title":"Lancet."},{"key":"1126_CR77","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","volume":"21","author":"A Thierry","year":"2020","unstructured":"Thierry, A. et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3. Lancet Oncol. 21, 1620\u20131629 (2020).","journal-title":"Lancet Oncol."},{"key":"1126_CR78","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-21-0271","volume":"27","author":"J Taieb","year":"2021","unstructured":"Taieb, J. et al. Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France trial. Clin. Cancer Res. 27, 5638\u20135646 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR79","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.24.00648","volume":"43","author":"J Tajeb","year":"2025","unstructured":"Tajeb, J. et al. Combined analyses of circulating tumor DNA and immunoscore in patients with stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France\/HORG-IDEA-Greece trials. J. Clin. Oncol. 43, 1564\u20131577 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1126_CR80","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2022","unstructured":"Henriksen, T. V. et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin. Cancer Res. 28, 507\u2013517 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR81","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","volume":"112","author":"H Taniguchi","year":"2021","unstructured":"Taniguchi, H. et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 112, 2915\u20132920 (2021).","journal-title":"Cancer Sci."},{"key":"1126_CR82","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura, Y. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat. Med. 30, 3272\u20133283 (2024).","journal-title":"Nat. Med."},{"key":"1126_CR83","doi-asserted-by":"publisher","first-page":"LBA22","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA22","volume":"43","author":"H Bando","year":"2025","unstructured":"Bando, H. et al. A randomized, double-blind, phase III study comparing trifluridine\/tipiracil (FTD\/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): the ALTAIR study [abstract]. J. Clin. Oncol. 43, LBA22 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1126_CR84","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1126_CR85","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat. Med. 31, 1509\u20131518 (2025).","journal-title":"Nat. Med."},{"key":"1126_CR86","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat. Med.  31, 4291\u20134300\u00a0(2025).","journal-title":"Nat. Med."},{"key":"1126_CR87","doi-asserted-by":"publisher","first-page":"S1268","DOI":"10.1016\/j.annonc.2023.10.020","volume":"34","author":"S Lonardi","year":"2023","unstructured":"Lonardi, S. et al. The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients [abstract LBA28]. Ann. Oncol. 34, S1268\u2013S1269 (2023).","journal-title":"Ann. Oncol."},{"key":"1126_CR88","doi-asserted-by":"publisher","first-page":"S474","DOI":"10.1016\/j.annonc.2025.08.1298","volume":"36","author":"S Marsoni","year":"2025","unstructured":"Marsoni, S. et al. Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: final results of the PEGASUS trial [abstract 723O]. Ann. Oncol. 36, S474 (2025).","journal-title":"Ann. Oncol."},{"key":"1126_CR89","first-page":"604","volume":"36","author":"IH Sahin","year":"2022","unstructured":"Sahin, I. H. et al. Minimal residual disease-directed adjuvant therapy for patients with early-stage colon cancer: CIRCULATE-US. Oncology 36, 604\u2013608 (2022).","journal-title":"Oncology"},{"key":"1126_CR90","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.annonc.2025.05.528","volume":"36","author":"RD Hofheinz","year":"2025","unstructured":"Hofheinz, R. D. et al. Localised rectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 36, 1007\u20131024 (2025).","journal-title":"Ann. Oncol."},{"key":"1126_CR91","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy, T. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 702\u2013715 (2021).","journal-title":"Lancet Oncol."},{"key":"1126_CR92","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-25-1242","volume":"31","author":"T Akiyoshi","year":"2025","unstructured":"Akiyoshi, T. et al. ctDNA longitudinal analysis during total neoadjuvant therapy and non-operative management for locally advanced rectal cancer: a biomarker study from the NOMINATE trial. Clin. Cancer Res. 31,\u00a05188\u20135197\u00a0(2025).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR93","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S1470-2045(25)00542-X","volume":"26","author":"A Amatu","year":"2025","unstructured":"Amatu, A. et al. Total neoadjuvant therapy followed by non-operative management or surgery in stage II-III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 26, 1612\u20131625 (2025).","journal-title":"Lancet Oncol."},{"key":"1126_CR94","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","volume":"5","author":"C Cremolini","year":"2019","unstructured":"Cremolini, C. et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 5, 343\u2013350 (2019).","journal-title":"JAMA Oncol."},{"key":"1126_CR95","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/s41416-020-01042-w","volume":"123","author":"T Masuishi","year":"2020","unstructured":"Masuishi, T. et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. Br. J. Cancer 123, 1490\u20131495 (2020).","journal-title":"Br. J. Cancer"},{"key":"1126_CR96","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11523-021-00845-y","volume":"16","author":"A Tsuji","year":"2021","unstructured":"Tsuji, A. et al. Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who obtained clinical benefit from first-line panitumumab-based chemotherapy: JACCRO CC-09. Target. Oncol. 16, 753\u2013760 (2021).","journal-title":"Target. Oncol."},{"key":"1126_CR97","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1200\/PO.20.00109","volume":"4","author":"Y Sunakawa","year":"2020","unstructured":"Sunakawa, Y. et al. RAS mutations in circulating tumor DNA and clinical outcomes of rechallenge treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer. JCO Precis. Oncol. 4, 898\u2013911 (2020).","journal-title":"JCO Precis. Oncol."},{"key":"1126_CR98","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","volume":"7","author":"E Martinelli","year":"2021","unstructured":"Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical cave trial. JAMA Oncol. 7, 1529\u20131535 (2021).","journal-title":"JAMA Oncol."},{"key":"1126_CR99","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11523-023-00963-9","volume":"18","author":"N Izawa","year":"2023","unstructured":"Izawa, N. et al. A phase II trial of trifluridine\/tipiracil in combination with cetuximab rechallenge in patients with RAS wild-type mCRC refractory to prior anti-EGFR antibodies: WJOG8916G trial. Target. Oncol. 18, 369\u2013381 (2023).","journal-title":"Target. Oncol."},{"key":"1126_CR100","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/ijc.34632","volume":"153","author":"S Napolitano","year":"2023","unstructured":"Napolitano, S. et al. Panitumumab plus trifluridine\/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: overall survival and subgroup analysis of the randomized phase II VELO trial. Int. J. Cancer 153, 1520\u20131528 (2023).","journal-title":"Int. J. Cancer"},{"key":"1126_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100120","volume":"7","author":"J Sgouros","year":"2025","unstructured":"Sgouros, J. et al. Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping. ESMO Gastrointest. Oncol. 7, 100120 (2025).","journal-title":"ESMO Gastrointest. Oncol."},{"key":"1126_CR102","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1200\/JCO.2025.43.16_suppl.3513","volume":"43","author":"L Weiss","year":"2025","unstructured":"Weiss, L. et al. FIRE-4 (AIO KRK-0114): randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab [abstract]. J. Clin. Oncol. 43, 3513 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1126_CR103","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","volume":"5","author":"J Tie","year":"2019","unstructured":"Tie, J. et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 5, 1710\u20131717 (2019).","journal-title":"JAMA Oncol."},{"key":"1126_CR104","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","volume":"30","author":"N Tarazona","year":"2019","unstructured":"Tarazona, N. et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann. Oncol. 30, 1804\u20131812 (2019).","journal-title":"Ann. Oncol."},{"key":"1126_CR105","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","volume":"27","author":"AR Parikh","year":"2021","unstructured":"Parikh, A. R. et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin. Cancer Res. 27, 5586\u20135594 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1126_CR106","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. 29, 127\u2013134 (2023).","journal-title":"Nat. Med."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01126-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01126-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01126-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:02:18Z","timestamp":1777032138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01126-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01126-1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"30 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.M. has received honoraria from Incyte, Pierre Fabre and Servier. S.N. has received personal fees from Novartis and a travel grant from Amgen. D.C. declares advisory board and\/or consultancy roles for Bayer, Foundation Medicine and Merck, and travel support from Bristol Myers Squibb, Merck and Sanofi. E.M. has served as an adviser and speaker for AstraZeneca, Eisai, Eli Lilly, Merck, Pfizer, Roche, Sanofi\/Genzyme and Servier outside the submitted work. T.T. has received travel grants from AstraZeneca and Pierre Fabre, and is an advisory board member for Amgen, AstraZeneca, Bayer, Merck, Pierre Fabre, Roche, Sanofi and Servier. M.G.Z. has received honoraria for advisory board roles from GSK. N.F. has received honoraria for consultancy and speaker roles from ITM Radiopharma and Novartis. G.C. has received speaker\u2019s honoraria from Bristol Myers Squibb, Celltrion, Foundation Medicine, Lilly, MSD, NanoString, Novartis, Pfizer, Roche, Samsung and Seattle Genetics; honoraria for consultancy roles from NanoString, Roche and Seattle Genetics; honoraria for participating in advisory boards from Celltrion, Foundation Medicine, Lilly, Mylan, Pfizer, Roche and Samsung; honoraria for writing engagement from Bristol Myers Squibb and Novartis; honoraria for participation in the Ellipsis Scientific Affairs Group; and institutional research funding for conducting phase I and II clinical trials from AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Janssen-Cilag, Medimmune, Medivation, Merck Serono, MSD, Novartis, Orion Therapeutics, Pfizer, Philogen, Roche, Sanofi, Seattle Genetics, Servier and Tesaro. F.C. has received institutional research grants from Amgen, Merck, MSD, Pfizer, Pierre Fabre, Roche and Servier; and has served on advisory boards for Bayer, Merck, MSD, Pierre Fabre, Roche and Servier. L.B.B. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}